I the Thank if like that to Edgemond's allocation interesting Hartaj, answer on great answer. for you, tag along little activities. might which highlight provide, capital organ between could bit with James, and R&D, I do has and - interface James manufacturing a our
effort, xenokidney been good So have the aimed to needs our dialysis progress we XXX,XXX Americans over of making are address which quite on unmet with medical today.
to believe won't die with much a of, Unfortunately, on as that a a waiting we We dialysis we've XX-gene as patients receive. effort, that what will to expect, many optimized life, the survival of them point repeatable, be having able kidney a but centers. of now reliable be better our quality a xenokidney in could dialysis they daily, that good would reached for be tethered transplant to not pig, provide on which
the want have facility want they more a a little six-by-six they see see color - us on is guided a have matrix, xenokidneys. of to into the bit to a that taking man FDA So the kind GMP-like they what before xenokidneys that plus key produce like threshold you to this, to give that
xenografts use or of for baboons, standard preclinical at untoward point with six is months a this evidence baboons model, to safety least to other the the into survival stands six-by-six months. the six put consequences the without which as infection baboons' for six So six six model six of at
abdomen. like small be human-size, large is on the six kilograms are to months, practical. baboon for simply reason the just are and designed order for The become after XX of months Baboons the which quite kidneys, six actually too
xenokidneys, have demonstrated six-month ones nine, kidneys, we repeatedly optimized are kidney. and of with finally over then kidneys, various five-gene like XX-gene survival our have that three-gene like So we versions on eight, this
out we're with what's also kidney XX-gene means calendar called xeno world we It is, our the of we - of parallel manufacture or year designated year, a for pig. to the space, situation In doing the we parlance, this, clean starting six facility how would so drugs, what the an And of in DPF. during baboons last XXXX. analogous pathogen-free built first, now, coming but a like in up organ
so the - it person. the would pig everybody that type harm xenokidney is a of criteria GMP viruses contain meets this confident to So that give any not coming that of does out
So our that modified facility. so into pig, we completed in achieve actually able we to should building genetically that the We've XXXX. goal the be six-by-six DPF C-sectioned facility first
to into We our first the go the have and should actually we running, xenokidneys and able up DPF be XXXX. in trials with clinical
that's us it's see to of So sort exciting near-term. that to tremendously
whole Now is, expect lot you. there's say, a a of - people consequence like they more good of the deed
that we if able the we to for to explode clinical in United XXXX, you of people demand with successfully people in waiting going xenokidneys, to so XXX,XXX are is the a complete on States. only showing half-year with can predicted rescue or a just dialysis have XXXX are xenokidney, who with left fact in a successfully study that can the life these So imagine kidney
of renal start every a kidneys could to more people up proportion about our XXX,XXX disease. have it's year, some And we of because So handle with not end-stage building down you like which appreciable whittle unfortunately, scale thinking year. XXX,XXX end facility, the
are many rescued, people as as are more being added. constantly So
million multi-hundred an facility. facility. even So demand certainly expensive a facility It's of to XX% like is that dollar a support say
organ destination wanted to additional on one our capital the - like manufacturing now explanation of tag the I kind James' completion like So will that perfect R&D-ish to of be just allocation facilities. manufacturing of
Operator, if you could please? queue question next up the
